TY - JOUR
T1 - Serum microRNA expression profile
T2 - MiR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma
AU - Takeshita, N.
AU - Hoshino, I.
AU - Mori, M.
AU - Akutsu, Y.
AU - Hanari, N.
AU - Yoneyama, Y.
AU - Ikeda, N.
AU - Isozaki, Y.
AU - Maruyama, T.
AU - Akanuma, N.
AU - Komatsu, A.
AU - Jitsukawa, M.
AU - Matsubara, H.
PY - 2013/2/19
Y1 - 2013/2/19
N2 - Background: Recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in blood and can serve as useful biomarkers for cancer. Methods: We performed an miRNA array using serum samples obtained from oesophageal squamous cell carcinoma (ESCC) patients or healthy controls. MiR-1246 was the most markedly elevated in ESCC patients. Therefore, miR-1246 was selected as a candidate for further analysis. The serum miR-1246 level in 46 healthy controls and 101 ESCC patients was evaluated and compared among various clinicopathological characteristics. MiR-1246 expressions in tissue, exosomal, and cellular samples were also examined. Results: Serum miR-1246 alone yielded an receiver-operating characteristic curve area of 0.754, with 71.3% sensitivity and 73.9% specificity for distinguishing ESCC patients from healthy controls. Serum miR-1246 was significantly correlated with the TNM stage and showed to be the strongest independent risk factor for poor survival (HR, 4.032; P=0.017). Unlike the tendency shown in previous reports, miR-1246 was not upregulated in ESCC tissue samples. Furthermore, exosomal miR-1246 did not reflect the abundance in the cell of origin. Conclusion: These data support our contention that serum miR-1246 has strong potential as a novel diagnostic and prognostic biomarker in ESCC, and its releasing mechanism is selective and independent of tissue miRNA abundance.
AB - Background: Recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in blood and can serve as useful biomarkers for cancer. Methods: We performed an miRNA array using serum samples obtained from oesophageal squamous cell carcinoma (ESCC) patients or healthy controls. MiR-1246 was the most markedly elevated in ESCC patients. Therefore, miR-1246 was selected as a candidate for further analysis. The serum miR-1246 level in 46 healthy controls and 101 ESCC patients was evaluated and compared among various clinicopathological characteristics. MiR-1246 expressions in tissue, exosomal, and cellular samples were also examined. Results: Serum miR-1246 alone yielded an receiver-operating characteristic curve area of 0.754, with 71.3% sensitivity and 73.9% specificity for distinguishing ESCC patients from healthy controls. Serum miR-1246 was significantly correlated with the TNM stage and showed to be the strongest independent risk factor for poor survival (HR, 4.032; P=0.017). Unlike the tendency shown in previous reports, miR-1246 was not upregulated in ESCC tissue samples. Furthermore, exosomal miR-1246 did not reflect the abundance in the cell of origin. Conclusion: These data support our contention that serum miR-1246 has strong potential as a novel diagnostic and prognostic biomarker in ESCC, and its releasing mechanism is selective and independent of tissue miRNA abundance.
UR - http://www.scopus.com/inward/record.url?scp=84875232250&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.8
DO - 10.1038/bjc.2013.8
M3 - 記事
C2 - 23361059
AN - SCOPUS:84875232250
SN - 0007-0920
VL - 108
SP - 644
EP - 652
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 3
ER -
